GlaxoSmithKline: You Are… A F*CKING DISGRACE!..

… according to some I presume?…

GlaxoSmithKline, the British drug giant, has agreed to pay $750 million to settle criminal and civil complaints that the company for years knowingly sold contaminated baby ointment and an ineffective antidepressant — the latest in a growing number of whistle-blower lawsuits that drug makers have settled with multimillion dollar fines.

Altogether, GlaxoSmithKline sold 20 drugs with questionable safety that were made at a huge plant in Puerto Rico that for years was rife with contamination. Cheryl Eckard, the company’s quality manager, asserts in her whistle-blower suit that she warned Glaxo of the problems but the company fired her instead of addressing the issues. Among the drugs affected were Avandia, Bactroban, Coreg, Paxil and Tagamet. No patients are known to have been sickened by the quality problems although such cases would be difficult to trace.

Eckard asserts that she warned Glaxo of the problems but the company fired her instead of addressing the issues.

TaxPayers Against Fraud spokesman Patrick Burns talks with Scott Drake
More at


Seroxat In China

In Europe and the US, Seroxat prescriptions have declined dramatically because of the notorious reputation of this SSRI drug to induce horrific side effects, but it seems even though Seroxat(Paxil) can cause suicide, homicide,addiction, severe withdrawal and birth defects, GSK is intent on milking sales of Seroxat until it bleeds the very bones out of people.

It just goes to show how devious these drug companies are, when they have been caught lying on one side of the world about the side effects of their drugs, they simply market it in emerging economies on the other side; they wait until the truth comes out there, and by that time they have made millions in profit, enough to provide a legal war chest as a shield against the inevitable future law suits….

The most widely-used antidepressants in China by the end of last year were GlaxoSmithKline’s Paxil/Seroxat (paroxetine) with a value market share of 18%, followed by Pfizer’s Zoloft (sertraline; 10%) and Eli Lilly’s Prozac (fluoxetine; also 10%). Lundbeck’s older drug Cipramil (citalopram), also sold by Xian-Janssen, and Lexapro had market shares of 6.5% and 3.0% respectively.

GSK Test New Malaria Vaccine In Kenya: Altruism Or Exploitation?

Isn’t it interesting how drug companies always seem to test their new drugs on Africans? (and those of the other poorer nations and states around the world). It would be nice to think this ‘altruism’ is about a duty of care to the worlds most vulnerable and poor, but as always with Big Bad Pharma, there are other agenda’s afoot. Malaria is rampant in Africa, but GSK have come up with a new drug which they claim will help this terrible disease. Recently, I drew attention to Pfizers wikileaks scandal regarding its dubious drug trial in Nigeria, GSK haven’t been accused of any wrong doing here, and on the surface it all looks above-board and ethical, in fact it could even maybe shine GSK in a good light…. But…

The most telling part of the article is the following…


Dr.Patricia Wambui Njuguna, Head of Research]:
“At this point with the vaccine that we are taking forward, this is what we have seen in previous trials, and we expect this to be the result from this trial but in future trial’s we do expect to develop a second generation vaccine which we hope will have higher efficacy.”

It’s a breakthrough moment that could start saving hundreds of thousands of lives by 2015 – although with a mere 50 percent success rate it is no panacea.

Scientists normally expect 80 percent success before a vaccine is rolled out but as GSK points out – even getting this far was thought impossible just a few years ago.

So it seems GSK claims a 50% success rate, but normally scientists expect an 80% success rate before the vaccine is tested widely on human subjects (guinea pigs)…

Hmmm.. perhaps that’s why GSK chose to roll it out in Kenya.. lax laws, desperate people..

Easy to exploit?..

for the rest of this article read on

British Company Testing its Malaria Vaccine in Kenya
2010-12-15 05:53

GlaxoSmithKline, the British-based drugmaker, is testing a new and promising vaccine on thousands of babies and young children. The clinic is located in Kenya where malaria is endemic.

Local mothers are queuing up to take part.

[Dama Ng’umbao, Mother]:
“Malaria is not good it is very bad, because it is a bad disease if you were to get it you would feel bad, not good at all.”

And often it is fatal.

The disease is caused by a parasite carried in the saliva of mosquitoes.

It’s the second biggest killer on earth after tuberculosis, claiming as many as 2.7 million lives a year, that is a life every 45 seconds.

The vaccine prevents the parasite from maturing and multiplying in the liver – stopping it from infecting the blood.

After more than two decades of painstaking laboratory work, the clinical case for the vaccine is almost proven.

[Dr.Patricia Wambui Njuguna, Head of Research]:
“At this point with the vaccine that we are taking forward, this is what we have seen in previous trials, and we expect this to be the result from this trial but in future trial’s we do expect to develop a second generation vaccine which we hope will have higher efficacy.”

It’s a breakthrough moment that could start saving hundreds of thousands of lives by 2015 – although with a mere 50 percent success rate it is no panacea.

Scientists normally expect 80 percent success before a vaccine is rolled out but as GSK points out – even getting this far was thought impossible just a few years ago.

Wikileaks And Pfizer : Big Bad Pharma Bastards?

Although this blog is primarily about the bad deeds of GlaxoSmithKline, occassionally the other big bad pharmaceutical companies catch my eye. This is a story about Pfizer’s notorious (allegedly illegal) clinical trials in Nigeria. After researching and documenting the pharmaceutical industry for some years now nothing really surprises me about the bad things it does, but this story is really quite shocking and i’m sure that the paralells with The Constant Gardener won’t be lost on some people. I know a little about the story but I haven’t been following it closely, so it is interesting to see that some information has been leaked on good old Wikileaks, from the Guardian, Read On:

WikiLeaks cables: Pfizer ‘used dirty tricks to avoid clinical trial payout’Cables say drug giant hired investigators to find evidence of corruption on Nigerian attorney general to persuade him to drop legal action

WikiLeaks cables: Pfizer ‘used dirty tricks to avoid clinical trial payout’Cables say drug giant hired investigators to find evidence of corruption on Nigerian attorney general to persuade him to drop legal action

Sarah Boseley, health editor, Thursday 9 December 2010 21.33 GMT Article history

Kano, in northern Nigeria, saw a meningitis epidemic of unprecedented scale in 1996.

The world’s biggest pharmaceutical company hired investigators to unearth evidence of corruption against the Nigerian attorney general in order to persuade him to drop legal action over a controversial drug trial involving children with meningitis, according to a leaked US embassy cable.
Pfizer was sued by the Nigerian state and federal authorities, who claimed that children were harmed by a new antibiotic, Trovan, during the trial, which took place in the middle of a meningitis epidemic of unprecedented scale in Kano in the north of Nigeria in 1996.

Last year, the company came to a tentative settlement with the Kano state government which was to cost it $75m.

But the cable suggests that the US drug giant did not want to pay out to settle the two cases – one civil and one criminal – brought by the Nigerian federal government.

The cable reports a meeting between Pfizer’s country manager, Enrico Liggeri, and US officials at the Abuja embassy on 9 April 2009. It states: “According to Liggeri, Pfizer had hired investigators to uncover corruption links to federal attorney general Michael Aondoakaa to expose him and put pressure on him to drop the federal cases. He said Pfizer’s investigators were passing this information to local media.”

The cable, classified confidential by economic counsellor Robert Tansey, continues: “A series of damaging articles detailing Aondoakaa’s ‘alleged’ corruption ties were published in February and March. Liggeri contended that Pfizer had much more damaging information on Aondoakaa and that Aondoakaa’s cronies were pressuring him to drop the suit for fear of further negative articles.”

The release of the Pfizer cable came as:

• The American ambassador to London denounced the leak of classified US embassy cables from around the world. In tomorrow’sGuardian Louis Susman writes: “This is not whistleblowing. There is nothing laudable about endangering innocent people. There is nothing brave about sabotaging the peaceful relations between nations on which our common security depends.”

• It emerged that Julian Assange had been transferred to the segregation unit in Wandsworth prison and had distanced WikiLeaks from cyber attacks on MasterCard, Visa, PayPal and other organisations.

• Other newly released cables revealed that China is losing patience with the failure of the Burmese regime to reform, and disclosed US fears that Europe will cave in to Serbian pressure to partition Kosovo.

While many thousands fell ill during the Kano epidemic, Pfizer’s doctors treated 200 children, half with Trovan and half with the best meningitis drug used in the US at the time, ceftriaxone. Five children died on Trovan and six on ceftriaxone, which for the company was a good result. But later it was claimed Pfizer did not have proper consent from parents to use an experimental drug on their children and there were questions over the documentation of the trial. Trovan was licensed for adults in Europe, but later withdrawn because of fears of liver toxicity.

The cable claims that Liggeri said Pfizer, which maintains the trial was well-conducted and any deaths were the direct result of the meningitis itself, was not happy about settling the Kano state cases, “but had come to the conclusion that the $75m figure was reasonable because the suits had been ongoing for many years costing Pfizer more than $15m a year in legal and investigative fees”.

In an earlier meeting on 2 April between two Pfizer lawyers, Joe Petrosinelli and Atiba Adams, Liggeri, the US ambassador and the economic section, it had been suggested that Pfizer owed the favourable outcome of the federal cases to former Nigerian head of state Yakubu Gowon.

He had interceded on Pfizer’s behalf with the Kano state governor, Mallam Ibrahim Shekarau – who directed that the state’s settlement demand should be reduced from $150m to $75m – and with the Nigerian president. “Adams reported that Gowon met with President Yar’Adua and convinced him to drop the two federal high court cases against Pfizer,” the cable says.

But five days later Liggeri, without the lawyers present, enlarged on the covert operation against Aondoakaa.

The cable says Liggeri went on to suggest that the lawsuits against Pfizer “were wholly political in nature”.

He alleged that Médecins sans Frontières, which was in the same hospital in Kano, “administered Trovan to other children during the 1996 meningitis epidemic and the Nigerian government has taken no action”.

MSF – which was the first to raise concerns about the trial – vehemently denies this. Jean-Hervé Bradol, former president of MSF France, said: “We have never worked with this family of antibiotic. We don’t use it for meningitis. That is the reason why we were shocked to see this trial in the hospital.”

There is no suggestion that the attorney general was swayed by the pressure. However, the dropping of the federal cases provoked suspicion in Nigeria. Last month, the Nigerian newspaper Next ran a story headlined, “Aondoakaa’s secret deal with Pfizer”.

The terms of the agreement that led to the withdrawal of the $6bn federal suit in October 2009 against Pfizer “remain unknown because of the nature of [the] deal brokered by … Mike Aondoakaa”, it said. Pfizer and the Nigerian authorities had signed a confidentiality agreement. “The withdrawal of the case, as well as the terms of settlement, is a highly guarded secret by the parties involved in the negotiation,” the article said.

Aondoakaa expressed astonishment at the claims in the US cable when approached by the Guardian. “I’m very surprised to see I became a subject, which is very shocking to me,” he said. “I was not aware of Pfizer looking into my past. For them to have done that is a very serious thing. I became a target of a multinational: you are supposed to have sympathy with me … If it is true, maybe I will take legal action.”

In a statement to the Guardian, Pfizer said: “The Trovan cases brought by both the federal government of Nigeria and Kano state were resolved in 2009 by mutual agreement. Pfizer negotiated the settlement with the federal government of Nigeria in good faith and its conduct in reaching that agreement was proper. Although Pfizer has not seen any documents from the US embassy in Nigeria regarding the federal government cases, the statements purportedly contained in such documents are completely false.

“As previously disclosed in Pfizer’s 10-Q filing in November 2009, per the agreement with the federal government, Nigeria dismissed its civil and criminal actions against the company. Pfizer denied any wrongdoing or liability in connection with the 1996 study. The company agreed to pay the legal fees and expenses incurred by the federal government associated with the Trovan litigation. Pursuant to the settlement, payment was made to the federal government’s counsel of record in the case, and there was no payment made to the federal government of Nigeria itself. As is common practice, the agreement was covered by a standard confidentiality clause agreed to by both parties.”

Wikileaks : Big Pharma Insider Whistleblower Cables..

You could call it the ecosystem of corruption. But it’s also all the regular decision making that turns a blind eye to and supports unethical practices: the oversight that’s not done, the priorities of executives, how they think they’re fulfilling their own self-interest. The way they talk about it

Let’s just walk through other industries. What about pharmaceutical companies? Yes. To be clear, we have so much unprocessed stuff, I’m not even sure about all of it. These are just things I’ve briefly looked at or that one of our people have told me about.

I’m sure everyone who’s got their finger on the pulse has by now heard of ‘wikileaks‘ . Personally I admire the courage and bravery of the ‘wikileaks’ organization. Not only have they shaken up the political elites across the globe with their recently leaked ‘diplomatic cables’ and internally classified memo’s, but it seems that they aim to release similar damning and revealing documents on the corrupt and unethical banking industry next year. And, if the rumors on the internet hold true, soon we will see just how corrupt, unethical and immoral the international pharmaceutical industry is too. (not that we don’t know already, but it’s nice to actually see the dirt rather than suspect that it exists) We are in the midst of world-wide information revolution folks and wikileaks is leading the way. I wonder how many GSK employees are partial to information that GlaxoSmithKilne would rather keep from users of their dodgy drugs. Are there any humane consciences out there amongst the GSK corporate minions? Some info on Avandia causing heart attacks perhaps? Internal memo’s on Seroxat causing suicide and horrific withdrawal maybe? Come on whistleblowers.. Ease that guilty conscience and do the right thing for your fellow human beings, blow that whistle on dirty pharma and hang them out for all the world to see…If you don’t do it, who will? … Big Pharma caught spying on the WHO December 10, 2009 By Kaitlin Mara (Intellectual Property Watch)[1] Confidential documents related to the World Health Organization Expert Working Group on innovative financing for research and development surfaced today, revealing the group’s thinking as well as pharmaceutical industry thinking about the WHO process. The documents immediately raised concern about possible undue access to the process by industry; the WHO told Intellectual Property Watch the industry group was not supposed to have the documents. The documents appear to have come from the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and include draft reports on innovative financing mechanisms from the working group as well as an analysis by the IFPMA on the reports’ contents. They were released on Wikileaks, a website that anonymously publishes sensitive documents. ”IFPMA was not supposed to have working drafts of the expert working group in their possession and they were not given these documents,” said Precious Matsoso, director of Public Health Innovation and Intellectual Property (PHI) at the WHO, under whose auspices the expert working group falls. “It was understood by the working group that its report is intended for the director general and” WHO members, she added. Public health advocates reacted strongly to the leaked documents. “The IFPMA document confirms much of what had been feared,” that there is “a larger WHO strategy to protect the status quo, particularly as it relates to intellectual property issues,” said James Love, the director of Knowledge Ecology International, a non-profit group focussed on transparency in policymaking and which has been advocating for prize funds, a biomedical R&D treaty, and other initiatives to fund R&D. An introductory letter included with the documents addressed to the Public Health Advocacy Committee at IFPMA says “the overall result [of the working group’s report] is in line with most of the industry positions on this matter,” but says that “there is still room for them to introduce new language” as the documents date from before the final working group meeting concluded on 2 December. The Expert Working Group’s “comparative analysis of innovative financing proposals for health R&D,” available from Wikileaks here [pdf], divides aspects of drug development into six categories and then lists the ideas from “least likely” to “most likely” to work. The six categories are: fundraising, research and development capacity building in developing countries, basic research and product discovery, product development, manufacturing and distribution, and efficiencies. The leaked documents are all available from Wikileaks here. Expert Analysis The draft reports available on Wikileaks do not contain final recommendations. These will be available only in the final report, expected to be released this week (IPW, WHO, 7 December 2009). Instead, it contains an analysis of all proposals made thus far, through two calls for advice from the public, and ranks them on efficacy and feasibility. Within “fundraising,” proposals considered “least likely to work” include diverting existing resources to health, reducing tax evasion and havens, levying new charges on services or access rights. A proposal for a “Green IP” system (IPW, Inside Views, 27 June 2008) is currently “too hard to operationalise” but some elements could potentially be useful. Most likely to work include new indirect taxes, for example on internet users; voluntary private contributions, new donor funds, and taxes on pharmaceutical profits. Taxing pharmaceutical profits is estimated to generate only USD 160 million versus, for example, a potential USD 2 billion from internet taxes. On building research capacity, specific recommendations are not made, but the report says there is a lot of potential in this idea as innovative pharmaceutical development is often done in commercial ventures and, in developing countries, “commercial targets often have significant overlap with public health targets,” as local markets demand treatment for neglected diseases. On basic research, prize systems and prize funds for completed drugs, as well as a “health impact fund,” are deemed least effective, as is the idea of a biomedical R&D treaty. “Endstage prizes” and the treaty were also seen as not particularly beneficial for product development. Prizes have been advocated as a solution to R&D financing problems by several health advocacy NGOs (IPW, Public Health, 12 February 2009). Deemed more effective in incentivising research were funding for product development partnerships, grants to companies working on neglected diseases, and prizes for reaching “milestones” (such as those provided by Innocentive). Similar incentives were considered beneficial for product development. Prizes were seen as possible incentives for manufacturing and distribution, though “likely only for diagnostics” as opposed to vaccines or medicines. “Absolutely Fair Towards the Industry” The draft report, the IFPMA said, is “absolutely fair” regarding industry concerns, using “real figures” on the cost of drug and vaccines developments and containing “many references to the importance of intellectual property … to achieve further innovation.” As far as streamlining the current R&D system, which the report calls “unwieldy,” removing data exclusivity was seen as less effective compared to harmonising medicine regulatory systems and “pre-competitive platforms” for R&D. The IFPMA analysis raised two major concerns. The first relates to proposed taxes on the pharmaceutical industry, which the IFPMA document says “places the burden of the R&D … exclusively on industry and reinforces the negative image of pharmaceutical profits.” “Operationalising this proposal may lead to companies increasing prices to compensate which would be counterproductive,” it adds. Further, it is not certain to be acceptable by all partners “as the tax should be imposed on the whole pharmaceutical sector, generic included.” The second area of concern is drug-purchasing mechanism UNITAID’s proposed patent pool, and in particular its structure for royalty payments to IP owners. These payments would be determined based on the “therapeutic benefits and the affordability of royalities in particular countries,” the analysis says, adding that this “does not follow past or current patent pool structures” and emphasising that voluntary participation should be an “essential prerequisite.” A UNITAID board meeting on 14-15 December will review an expert study on the patent pool, which the UNITAID board agreed in principle to establish in July 2008. In May 2009, the board instructed the organisation’s secretariat to prepare an implementation plan. An expert team analysed a range of issues and its report, completed in November, clearly recommends the implementation of the pool, sources told Intellectual Property Watch. The IFPMA analysis also called for vigilance regarding the potential use of open source systems. NGOs: Documents “A Step Backwards” Love said the expert working group process was “a step backwards” and “evidence of a deeper problem in WHO regarding the influence of the pharmaceutical industry, and its philanthropic supporter, the Microsoft founder’s Gates Foundation.” ”This is a very disturbing set of documents,” said Sarah Rimmington, from nongovernmental organization Essential Action’s Access to Medicines Project. She added that the report “embraces the status quo and rejects the feasibility of almost every single important proposal aimed at truly solving these complicated problems.” Kaitlin Mara may be reached at Check Out This Video From Fox News : December 1, 2010 Wikileaks Targets Big Pharma Attorney Mark Lanier on why Wikileaks is going after drug companies and how it might impact future lawsuits.

Rob Robinson : Seroxat Activist …

Just For The Hell Of It….

Dear Paxil/Seroxat Victim,

Not only did GlaxoSmithKline con you into taking PAXIL (Seroxat in the U.K.) — along with your healthcare provider who unwittingly prescribed it — untold numbers of you are addicted to it now. Which is a good thing since we at GSK are addicted to corporate profits (see GlaxoSmithKline 1997 confidential company document* at right) and, quite frankly, could care less about the pain and misery, the suffering and even death, that Paxil has spawned — as a direct result of our fraudulent promotion of the drug.

In fact, as far as GSK is concerned your health and well-being is on a par level with that of a disposable lab rat. On second thought maybe that’s a little too harsh; I’m not suggesting we don’t value you … far from it. After all, lab rats don’t have healthcare plans or bank accounts that can pay to have Paxil prescriptions filled. Yes?

If you’re like many Paxil users at some point you figured out you couldn’t stop taking “the drug” without experiencing oftentimes severe and distressing symptoms … electroshock sensations radiating throughout your head for instance. And that, of course, is just for starters. Isn’t it great! For us, I mean. See, you have to keep taking Paxil to make the discontinuance, I mean withdrawal, symptoms stop. (We had to start using the word “withdrawal” a few years ago after some do-gooder lawyers from California sued us.)

Of course, many of you risked it all to escape from our “Alcatraz in a pill bottle” — and lived to tell about it. And thousands of you are suing us in the U.S. and Britain … all because of that one little silly word. (Hundreds of you have also sued us because someone in your family killed themselves right after they started taking Paxil, or while they were trying to stop taking it, but we’re quietly settling all of those cases out of court so let’s not even talk about that. Its not a pleasant subject.)

I’ve got a lot more I’d like to share with you in this open letter and indeed I will likely expand it a bit more later on, but I’m getting all misty eyed at the moment as I think of all the dedicated Paxil addicts working hard and dutifully taking their daily dose of rat poison, I mean, Paxil — so GSK can continue raking in billions of dollars in Paxil profits every year. It’s a beautiful thing you know. Our scheme, that is.

Anyway, let’s have some fun shall we? Happy smiling faces and all that. Immediately following this letter you’ll find some of the neat stuff GSK is working to bring to your cyber doorstep. We hope you enjoy it, and believe it’s the least we can do. It’s all about being a good corporate citizen.

Finally, before I forget … on behalf of all of us at GLAXOSMITHKLINE I’d like to say “”thank you” — and don’t forget to “EAT MORE PAXIL” (Otherwise I won’t be able to afford upkeep for my assortment of multi-million dollar homes (and ski bungalows: one in Aspen, Colorado and another in the French Alps), maintain my Leer jet, my sports cars ( a Lamborgini and a Porsche), monthly restocks of my wine cellar … you get the idea.


J.P. Garnier, CEO


*What we (GSK) knew about Paxil when it was first developed — and didn’t tell you (or your physician.)


*A special “thank you” note to everyone who chose to become a Paxil addict.

*A “thank you” note to employees of the FDA who accepted bribes from GSK (then SKB) to allow Paxil into the marketplace, and helped those people thanked above (become addicts.)

*GSK’s “Paxil Suicide Hall of Fame.” Dedicated to those Paxil victims for whom “Paxil addiction just wasn’t enough.” Located in GSK’s Philadelphia, PA headquarters.


*A (generous) $25 gift certificate redeemable online at “Flowers-R-Us” for survivors of Paxil suicides.

*A (super generous) $100 credit towards the purchase of a grave marker for children who killed themselves whilst taking or withdrawing from Paxil.

*A (generous) $75 gift certificate good towards the purchase of Post Traumatic Stress Disorder self-help books (for Paxil withdrawal-induced PTSD.)


*A book of poems penned by GSK employees; inspired by fantasies of your Paxil withdrawal.

*A pamphlet entitled “Bad Paxil Withdrawals And How To Have Them.”

*A book of Paxil withdrawal jokes authored by top GSK executives.

*A one-year subscription to “The Zaps” (a comic book series that “looks at the lighter side” of this pesky Paxil withdrawal symptom.)

*A two volume set entitled “Welcome To The Abyss: A Paxil Withdrawee’s Field Guide To PaxHell.”

*A do-it-yourself Paxil withdrawal guide. Note: DOES NOT include information about converting over to a competitor’s product (Prozac) when tapering from Paxil doesn’t work.

*A cute, GSK children’s cartoon coloring book entitled “Paxil Withdrawal Hell: Why Do I Want To Kill Myself, Mommy.”

*“Dante’s Inferno: The Paxil Sequel” by GSK President J.P. Garnier. Note: leatherbound with engraved gold lettering.

*“The Myth Of Paxil Withdrawal” by GSK’s Minister of Paxil Propaganda, Dr. Alistair Benbow. A 300 page tome, of which 299 pages are blank. Page one simply says “Whilst I have every sympathy for anyone who may have suffered side effects whilst taking Paxil … I still must say its only discontinuance syndrome.”

*An information leaflet entitled “Discontinuance Syndrome: Defined At Last.” (I’ll save you some time … Discontinuance Syndrome is the phenomenon whereby countries ban or severely restrict the distribution of Paxil.)

*“Dancing Behind GSK’s Corporate Veil: How To Rape And Pillage For Drug Profits, Maintain Personal Anonymity, Avoid Personal Accountability And Sidestep Liability.” A huge block of a book, with contributions by numerous GSK top execs.

*Let Them Eat Rat Poison” by Dr. Anne Phillips, Vice President, Research & Development and Chief Medical Officer, GSK. Reviewed by the “Prisoner of Paxil” who wrote “an insightful book which provides the reader with a clear understanding as to why Paxil was turned loose an unsuspecting public. As Dr. Phillips says in her foreward “Its all about the money, BABY! Yahoo!”

*”Poisoning People With Paxil For Fun And Profit” by GSK spokesperson Mary Ann Rhyne. A frank discussion of the critical components needed to pull off a massive corporate drug fraud, including: dummied up field studies, successful collusion with insiders at public institutions (like the FDA), how to silence Paxil victims by buying them off (for pennies on the dollar) and more!

*“The Living Dead: Human Paxil Lab Rats And How To Trap Them” by Dr. Philip Perera, psychiatrist and group director for clinical psychiatric research at GSK.

*A GSK consumer leaflet entitled “So You Had Millions Of Nuerons Fried By Paxil Withdrawal … So What Now?” How to “rebuild your withdrawal-damaged brain” using common household items like superglue and duct tape.


*A t-shirt emblazoned with the line: “I Went Through Paxil Withdrawal Hell … And All I Got Was This Lousy T-Shirt.” An eye-catching graphic on the back of the shirt depicts a crumpled human body fused to a dead rat’s head.


*A glossy 8” x 10” color photo of GSK’s Minister of Paxil Propaganda, Dr. Alistair Benbow being quoted as saying “Whilst I have every sympathy….” Suitable for framing. Signed. Limited printing.

*A DVD of Dr. Alistair Benbow receiving the Dr. Joseph Mengele Award of Excellence on behalf of GSK. Presented by several still-living members of the defunct Third Reich. “Rich in sentimental value.”

*A four-color, two-panel poster. Panel #1 depicts a GSK employee poised to drop a replica of an oversized human brain into the maw of a commercial-grade wood chipper. Subtitle: “This is your brain before Paxil withdrawal.” The second panel depicts a close up shot of a chipped pile of gore. Subtitle: “This is your brain going through Paxil withdrawal. Any questions?”

*A free poster reproduction of Munch’s “The Scream” subtitled “Paxil Withdrawal: My Trip To Hell On Earth.” (Suitable for framing.)

*A four color poster of an exposed human brain capped by an atomic mushroom cloud. Subtitled with a quote from GSK President J.P. Garnier who exclaims “Paxil withdrawal — ain’t it a blast!”

*A computer screen saver of Hieronymous Bosch’s depiction of Hell … with your own image scanned into the scene — along with a legion of Paxil pills chasing you to and fro amongst the flames. Specify Mac or Windows when ordering.

*A free bumper sticker “Paxil withdrawal … are we having fun yet?!”

*An 8” by 10” full color photograph of GSK President J.P. Garnier displaying an oversized Paxil pill bottle in one hand — and the dismembered head of a small child (who died whilst in Paxil withdrawal) dangling by its hair in the other. Taken at a recent corporate retreat in Aspen, Colorado.

*An autographed, four-color poster of GSK spokesperson and Paxil CR chompin’ NFL legend Terry Bradshaw — who told an interviewer in 1980 “I’m just going to answer as openly and honestly as I possibly can. And when I think it’s really controversial, I’ll just lie.” (Second Bradshaw poster with inscribed quote available as follows: When asked by the same interviewer “Were you ever at a point where you were just curious to try a drug — to see what it would do?” Bradshaw replied “No, I never cared anything about it. All I’ve heard about drugs is bad, so why get hooked on something that’s bad? You know. As the old cat says, I’m high on life, pardner.”

* A bumper sticker that reads “Terry Bradshaw Says: Eat More Paxil”.


*A miniature Telsa coil. Sprays electrical energy throughout a small globe mounted on a special, insulated stand. (So when someone visits you at home and asks you “what do you mean you have ‘the zaps’” … you can turn this device on and show them what’s happening inside your head.) Free, but quantities are limited.

*A gold-plated .32 caliber revolver, butt-inscribed with a calligraphic quote by GSK President J.P. Garnier that reads: “Good luck with your Paxil withdrawal.” Note: this is an on-line auction item. Date to be announced.

*A sterling silver, serrated 12” butcher knife, face-inscribed with a calligraphic quote by GSK spokesperson Michael Fleming that reads: “Here’s ‘a little helper’ in case your Paxil withdrawal goes really, really bad. But remember, Paxil has helped millions and millions of people….”

*A miniature bronze statue of GSK’s 2004 Employee of the Year, legal counsel Daniel Troy, who worked “in field” for GSK at the Food and Drug Administration’s Washington office.

*A football-sized Paxil pill autographed by GSK spokesperson and sports celebrity … Paxil CR chompin’ NFL legend Terry Bradshaw.

*A giant rat trap (scaled to human size) baited with a bottle full of Paxil pills. Mahogany base plate. A perfect conversation piece to add “a bit of spice” to any Paxil victim’s living room decor. Note: Not suitable for display in homes with children.

*A free (oversized) campaign-style button that reads: “Paxil withdrawal … are we having fun yet?!”

*A life-sized puppet replica of Dr. Mark McClellan, former head of the Food and Drug Administration. Strings included!

*”Paxil Withdrawal — The Board Game.” (Similar in theme to Monopoly.) Sorry, no “get out of Paxhell free” cards included. Game pieces are color-coded Paxil tablets in various milligram doses.


*A pair of free concert tickets to see the GSK-sponsored rock group the “Global Serial Killers.” Top stage hits include: “Off Label Them Kiddies (But Don’t Off’em),” “PANES Ain’t Such A Pain,” “Discontinuance Syndrome Blues,” “Benbow Ain’t No Boogieman,” “Welcome … To The Paxiltorium,” and “Human Lab Rats.”

*And for your “at home” or “in car” listening pleasure … GSK’s top-selling CD. Includes chart smashers like: “Night of a Thousand Nightmares,” “Tinnitus Symphony,” “I Forgot To Take My Paxil (and Went on a Murderous Rampage),” “Ode to Alistair (Symphony From Hell, Part I),” “Voulez-Vous Coucher Avec Moi, Jean-Pierre? (I Promise I Won’t Kill You)” and “They Said It Wasn’t Addictive.”

*A pair of complementary tickets to see the opening of “PaxHell —The Musical.” Features a dance corps comprised of GSK execs (and their goons at the FDA) singing the opening song “We Hooked Them.”


*An essay contest for Paxil withdrawees afflicted by PANES (Persistent Adverse Neurological Effects and Symptoms.)

*An on-line application to register for a free stay at GSK’s legendary “Paxiltorium.” Hot Tip: Be sure to register well before your Paxil withdrawal force feeds your sanity through the bio-equivalent of a high speed paper shredder.

*PaxHell — “The Reality Show.” PaxHell is a real life drama, hosted by GSK’s own Dr. Alistair Benbow, consisting of ten “contestants” suffering through various stages of Paxil withdrawal … whist living together in a beautiful resort home owned by GSK (normally reserved for GSK execs to vacation at.) A GSK weekly webcast of the show includes “all the best clips” from each week’s episode. Tension on the set is heightened by the lack of informed medical help, and a paucity of contestant knowledge regarding how to best get off the drug. If they can! LOL See contestant’s daily struggle to hang onto their sanity as they are assaulted by “the zaps,” vertigo, projectile vomiting, fainting spells, severe tinnitus, hypervivid nightmares, hallucinations, murderous headaches, tremors, chronic insomnia, heart palpitations, chest convulsions, severe and excruciating joint pain — and lots more! Withdrawees who manage to stave off suicide win an all expense paid trip to the U.K. to tour GSK’s world headquarters, followed by a bonus trip to Yugoslavia to meet with some of the survivors of Paxil’s early “dummied” clinical trials. And finally, any (surviving) contestants beset by withdrawal-induced PTSD or PANES are given a special “thank you for being such a trooper” plaque … presented in person by none other than GSK’s CEO J.P. Garnier himself. WOW!

*Note: The GlaxoSmithKline document displayed at the top of this page is authentic; it was first used in an ABC news expose in late 2004. See for the story along with several other GSK confidential documents.

Visit The Paxil Protest for more….

GlaxoSmithKline In The Dock Again!…

Old Corporate Bad Habits Die Hard …

Former Glaxo Lawyer Goes To Trial In February
Make a comment
By Ed Silverman // December 2nd, 2010 // 8:23 am

Lauren Stevens, the former GlaxoSmithKline attorney, appeared in federal court yesterday and pleaded not guilty to a bunch of charges that generated enormous publicity last month. That’s because her indictment marked a rare moment when the federal government decided to hold a relatively high-ranking pharma employee accountable for an alleged off-label marketing infraction. She now faces an estimated three-week trial beginning on Feb. 1 (see this).
Specifically, Stevens was charged with one count of obstructing an official proceeding, one count of concealing and falsifying documents to influence a federal agency, and five counts of making false statements to the FDA (read the indictment). The indictment states that in October 2002, the FDA asked for info about promotion of Wellbutrin XR, as part of an inquiry into off-label marketing (back story here).
The trial, which will be held in US District Court in Maryland, should be fascinating. You may recall that her attorney, Brien O’Connor of Ropes & Gray, declared last month that “everything she did in this case was consistent with ethical lawyering and the advice provided her by a nationally prominent law firm retained by her employer specifically because of its experience in working with FDA.”
What might this mean? The trial may offer up the spectacle of a former Glaxo attorney – who is now officially retired, by the way – pointing fingers at one or more attorneys who billed Glaxo and, most likely, other large drugmakers on a regular basis. And perhaps Stevens and O’Connor will also look to pin some blame on other Glaxo personnel in the general counsel’s office and elsewhere. But imagine a courtroom filled with pharma lawyers also shouting ‘J’accuse!’ at one another for three weeks? This has the makings of high drama, yes?